Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression
Overview
- Phase
- Not Applicable
- Intervention
- memantine
- Conditions
- Major Depressive Disorder
- Sponsor
- Jerrry L Lewis
- Locations
- 1
- Primary Endpoint
- Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.
- Status
- Withdrawn
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.
Detailed Description
Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.
Investigators
Jerrry L Lewis
Principal Investigator
University of Iowa
Eligibility Criteria
Inclusion Criteria
- •Meets criteria for Major Depressive disorder
Exclusion Criteria
- •Neurological disease
- •Mental retardation
- •Seizure disorder
Arms & Interventions
Memantine arm
Patient receiving ECT and Memantine
Intervention: memantine
placebo
25 patients receiving ECT will will receive placebo
Intervention: memantine
placebo
25 patients receiving ECT will will receive placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.
Time Frame: 6 to 8 weeks
Secondary Outcomes
- Whether memantine will improve response of Depression to Electroconvulsive therapy.(6-8 weeks)